New standardised, contemporary strain panels address a long-standing barrier in AMR research

PACE (Pathways to Antimicrobial Clinical Efficacy) and the UK Health Security Agency (UKHSA) have released five new contemporary antimicrobial resistance (AMR) strain panels, giving innovators worldwide a resource to test novel therapeutics and diagnostics against today’s resistance patterns.

Medicines Discovery Catapult appoints global life science and commercialisation leaders to its Board of Directors

New appointments support MDC’s mission to turn drug discovery into commercial breakthroughs.

Inspiring the next generation: Medicines Discovery Catapult scientist contributes to children’s science book 

Dr Emma Jones, a Lead Scientist in in vitro Neurobiology at Medicines Discovery Catapult (MDC), has contributed to a new children’s book celebrating the diversity of careers in science.

Medicines Discovery Catapult invests in UK biotech pioneers developing novel treatments for chronic diseases

Investment and expert support will help accelerate the development of new treatments for a range of autoimmune, inflammatory, and age-related diseases.

UK Intracellular Drug Delivery Centre opens for industry access to accelerate next-generation RNA medicines 

The centre will provide integrated expertise and evidence generation to help innovators accelerate the development of next-generation RNA medicines.

The BARBARA Alliance launches to accelerate dementia clinical trials and unlock new treatments

The Francis Crick Institute and Medicines Discovery Catapult Open KQ Labs Applications, Accelerating the Next Wave of Data-Driven Health Innovation 

Medicines Discovery Catapult selects prominent UK life sciences leader,  Professor Sir Mike Ferguson, as its incoming Chair of the Board 

Deep Science Ventures and Medicines Discovery Catapult Partner to Accelerate Next‑Generation Brain Treatments